Erratum: MicroRNA-22 functions as a tumor suppressor by targeting SIRT1 in renal cell carcinoma(Oncol Rep (2016) 35 (559‑567) DOI: 10.3892/or.2015.4333);MicroRNA-22 functions as a tumor suppressor by targeting SIRT1 in renal cell carcinoma

Oncology Reports

Volumn 35, Issue 1, 2016, Pages 559-567

  Zhang, Shoulin ^a   Zhang, Dongmei ^a   Yi, Chunguang ^a   Wang, Yinping ^a   Wang, Hongan ^a   Wang, Jian ^a  

^a CHANGCHUN UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

MiR 22; P53; Renal cell carcinoma; SIRT1

Indexed keywords

CASPASE 3; MICRORNA 22; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN P21; PROTEIN P53; PUMA PROTEIN; SIRTUIN 1; 3' UNTRANSLATED REGION; MICRORNA; MIRN22 MICRORNA, HUMAN; SIRT1 PROTEIN, HUMAN;

ADULT; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER STAGING; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL FEATURE; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION; GENE FUNCTION; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; KIDNEY CARCINOMA; LUCIFERASE ASSAY; LYMPH NODE METASTASIS; MALE; METASTASIS INHIBITION; NUDE MOUSE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; 3' UNTRANSLATED REGION; ANIMAL; CANCER TRANSPLANTATION; GENE EXPRESSION REGULATION; GENETICS; KIDNEY TUMOR; METABOLISM; MOUSE; PATHOLOGY; TUMOR CELL LINE;

3' UNTRANSLATED REGIONS; ANIMALS; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KIDNEY NEOPLASMS; MALE; MICE; MICRORNAS; NEOPLASM TRANSPLANTATION; SIRTUIN 1;

EID: 84954065789     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2021.8194     Document Type: Erratum

References (39)

1. Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA Cancer J Clin 64: 9-29, 2014.
2. DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, Alteri R, Robbins AS and Jemal A: Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin 64: 252-271, 2014.
3. Chow WH, Dong LM and Devesa SS: Epidemiology and risk factors for kidney cancer. Nat Rev Urol 7: 245-257, 2010.
4. Pantuck AJ, Zisman A and Belldegrun AS: The changing natural history of renal cell carcinoma. J Urol 166: 1611-1623, 2001.
5. Dibiase SJ, Valicenti RK, Schultz D, Xie Y, Gomella LG and Corn BW: Palliative irradiation for focally symptomatic metastatic renal cell carcinoma: Support for dose escalation based on a biological model. J Urol 158: 746-749, 1997.
6. Fabian MR, Sonenberg N and Filipowicz W: Regulation of mRNA translation and stability by microRNAs. Annu Rev biochem 79: 351-379, 2010.
7. Guo H, Ingolia NT, Weissman JS and Bartel DP: Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 466: 835-840, 2010.
8. Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 116: 281-297, 2004.
9. McManus MT: MicroRNAs and cancer. Semin Cancer Biol 13: 253-258, 2003.
10. Farazi TA, Spitzer JI, Morozov P and Tuschl T: miRNAs in human cancer. J Pathol 223: 102-115, 2011.
11. Garzon R and Marcucci G: Potential of microRNAs for cancer diagnostics, prognostication and therapy. Curr Opin Oncol 24: 655-659, 2012.
12. Kong LM, Liao CG, Zhang Y, Xu J, Li Y, Huang W, Zhang Y, Bian H and Chen ZN: A regulatory loop involving miR-22, Sp1, and c-Myc modulates CD147 expression in breast cancer invasion and metastasis. Cancer Res 74: 3764-3778, 2014.
13. Guo S, Bai R, Liu W, Zhao A, Zhao Z, Wang Y, Wang Y, Zhao W and Wang W: miR-22 inhibits osteosarcoma cell proliferation and migration by targeting HMGb1 and inhibiting HMGb1-mediated autophagy. Tumour biol 35: 7025-7034, 2014.
14. Yang C, Ning S, Li Z, Qin X and Xu W: miR-22 is down-regulated in esophageal squamous cell carcinoma and inhibits cell migration and invasion. Cancer Cell Int 14: 138, 2014.
15. Wang X, Yu H, Lu X, Zhang P, Wang M and Hu Y: miR-22 suppresses the proliferation and invasion of gastric cancer cells by inhibiting CD151. Biochem Biophys Res Commun 445: 175-179, 2014.
16. Zhang G, Xia S, Tian H, Liu Z and Zhou T: Clinical significance of miR-22 expression in patients with colorectal cancer. Med Oncol 29: 3108-3112, 2012.
17. Song SJ and Pandolfi PP: miR-22 in tumorigenesis. Cell Cycle 13: 11-12, 2014.
18. He H, Wang L, Zhou W, Zhang Z, Wang L, Xu S, Wang D, Dong J, Tang C, Tang H, et al: MicroRNA expression profiling in clear cell renal cell carcinoma: Identification and functional validation of key miRNAs. PLoS One 10: e0125672, 2015.
19. Vaziri H, Dessain SK, Ng Eaton E, Imai SI, Frye RA, Pandita TK, Guarente L and Weinberg RA: hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 107: 149-159, 2001.
20. Langley E, Pearson M, Faretta M, Bauer UM, Frye RA, Minucci S, Pelicci PG and Kouzarides T: Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence. EMBO J 21: 2383-2396, 2002.
21. Li JY, Yong TY, Michael MZ and Gleadle JM: Review: The role of microRNAs in kidney disease. Nephrology (Carlton) 15: 599-608, 2010.
22. Xiao H, Zeng J, Li H, Chen K, Yu G, Hu J, Tang K, Zhou H, Huang Q, Li A, et al: miR-1 downregulation correlates with poor survival in clear cell renal cell carcinoma where it interferes with cell cycle regulation and metastasis. Oncotarget 6: 13201-13215, 2015.
23. Qiu M, Liang Z, Chen L, Tan G, Wang K, Liu L, Liu J and Chen H: MicroRNA-429 suppresses cell proliferation, epithelial-mesenchymal transition, and metastasis by direct targeting of BMI1 and E2F3 in renal cell carcinoma. Urol Oncol 33: 332.e9-e18, 2015.
24. Li X, Xin S, He Z, Che X, Wang J, Xiao X, Chen J and Song X: MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor PDCD4 and promotes cell transformation, proliferation, and metastasis in renal cell carcinoma. Cell Physiol biochem 33: 1631-1642, 2014.
25. Gurha P, Abreu-Goodger C, Wang T, Ramirez MO, Drumond AL, van Dongen S, Chen Y, Bartonicek N, Enright AJ, Lee B, et al: Targeted deletion of microRNA-22 promotes stress-induced cardiac dilation and contractile dysfunction. Circulation 125: 2751-2761, 2012.
26. Pasqualini L, Bu H, Puhr M, Narisu N, Rainer J, Schlick B, Schäfer G, Angelova M, Trajanoski Z, Börno ST, et al: miR-22 and miR-29a are members of the androgen receptor cistrome modu lating LAMC1 and Mcl-1 in prostate cancer. Mol Endocrinol 29: 1037-1054, 2015.
27. Xiong JI, Yu D, Wei N, Fu H, Cai T, Huang Y, Wu C, Zheng X, Du Q, Lin D, Liang Z: An estrogen receptor alpha suppressor, microRNA-22, is downregulated in estrogen receptor alpha-positive human breast cancer cell lines and clinical samples. FEBS J 277: 1684-1694.
28. Poliseno L, Salmena L, Riccardi L, Fornari A, Song MS, Hobbs RM, Sportoletti P, Varmeh S, Egia A, Fedele G, et al: Identification of the miR-106b∼25 microRNA cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformation. Sci Signal 3: ra29, 2010.
29. Dong YJ, Liu N, Xiao Z, Sun T, Wu SH, Sun WX, Xu ZG and Yuan H: Renal protective effect of sirtuin 1. J Diabetes Res 2014: 843786, 2014.
30. Huffman DM, Grizzle WE, Bamman MM, Kim JS, Eltoum IA, Elgavish A and Nagy TR: SIRT1 is significantly elevated in mouse and human prostate cancer. Cancer Res 67: 6612-6618, 2007.
31. Jang KY, Kim KS, Hwang SH, Kwon KS, Kim KR, Park HS, Park BH, Chung MJ, Kang MJ, Lee DG, et al: Expression and prognostic significance of SIRT1 in ovarian epithelial tumours. Pathology 41: 366-371, 2009.
32. Jung YJ, Lee JE, Lee AS, Kang KP, Lee S, Park SK, Lee SY, Han MK, Kim DH and Kim W: SIRT1 overexpression decreases cisplatin-induced acetylation of NF-κb p65 subunit and cytotoxicity in renal proximal tubule cells. Biochem Biophys Res Commun 419: 206-210, 2012.
33. Stünkel W, Peh BK, Tan YC, Nayagam VM, Wang X, Salto-Tellez M, Ni B, Entzeroth M and Wood J: Function of the SIRT1 protein deacetylase in cancer. Biotechnol J 2: 1360-1368, 2007.
34. Chen J, Zhang B, Wong N, Lo AW, To KF, Chan AW, Ng MH, Ho CY, Cheng SH, Lai PB, et al: Sirtuin 1 is upregulated in a subset of hepatocellular carcinomas where it is essential for telomere maintenance and tumor cell growth. Cancer Res 71: 4138-4149, 2011.
35. Yamakuchi M, Ferlito M and Lowenstein CJ: miR-34a repression of SIRT1 regulates apoptosis. Proc Natl Acad Sci USA 105: 13421-13426, 2008.
36. Xu JQ, Liu P, Si MJ and Ding XY: MicroRNA-126 inhibits osteosarcoma cells proliferation by targeting Sirt1. Tumour biol 34: 3871-3877, 2013.
37. Deng S, Zhu S, Wang B, Li X, Liu Y, Qin Q, Gong Q, Niu Y, Xiang C, Chen J, et al: Chronic pancreatitis and pancreatic cancer demonstrate active epithelial-mesenchymal transition profile, regulated by miR-217-SIRT1 pathway. Cancer Lett 355: 184-191, 2014.
38. Zhang H, Feng Z, Huang R, Xia Z, Xiang G and Zhang J: MicroRNA-449 suppresses proliferation of hepatoma cell lines through blockade lipid metabolic pathway related to SIRT1. Int J Oncol 45: 2143-2152, 2014.
39. Liu Y, Li X, Zhu S, Zhang JG, Yang M, Qin Q, Deng SC, Wang B, Tian K, Liu L, et al: Ectopic expression of miR-494 inhibited the proliferation, invasion and chemoresistance of pancreatic cancer by regulating SIRT1 and c-Myc. Gene Ther: Apr 28, 2015 (Epub ahead of print). doi:10.1038/gt.2015.39.